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Abstract
Purpose: The purpose of this review is to compare the effectiveness of induction therapy with arsenic
trioxide (ATO) paired with retinoic acid (ATRA) and standard chemotherapy for the treatment of newly
diagnosed acute promyelocytic leukemia (APL).
Background and Significance: The use of chemotherapy for APL treatment has demonstrated successful
results, but is associated with toxicities. Research has shown that the use of ATO/ATRA not only achieves
complete molecular remission, but also increased survival rates and reduced disease relapse.
Methods: Databases used include CINAHL, PubMed, and ProQuest Nursing and Allied Health. Keywords
searched were induction treatment, acute promyelocytic leukemia, arsenic trioxide, retinoic acid, and
chemotherapy-free.
Results: Overall, patients who received ATO/ATRA compared to those who were treated with ATRA alone
or ATRA with chemotherapy demonstrated better event-free survival, less disease relapse, and required
less supportive care.
Discussion: Results confirm that the use of ATO/ATRA is the superior choice of induction therapy for
patients newly diagnosed with low-risk APL.
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Arsenic: It’s Not Just for Rats.
The Benefits of Arsenic Trioxide for the Treatment of Acute Promyelocytic Leukemia
Abstract
Purpose: The purpose of this review is to compare the effectiveness of induction therapy with
arsenic trioxide (ATO) paired with retinoic acid (ATRA) and standard chemotherapy for the
treatment of newly diagnosed acute promyelocytic leukemia (APL).
Background and Significance: The use of chemotherapy for APL treatment has demonstrated
successful results, but is associated with toxicities. Research has shown that the use of
ATO/ATRA not only achieves complete molecular remission, but also increased survival rates
and reduced disease relapse.
Methods: Databases used include CINAHL, PubMed, and ProQuest Nursing and Allied Health.
Keywords searched were induction treatment, acute promyelocytic leukemia, arsenic trioxide,
retinoic acid, and chemotherapy-free.
Results: Overall, patients who received ATO/ATRA compared to those who were treated with
ATRA alone or ATRA with chemotherapy demonstrated better event-free survival, less disease
relapse, and required less supportive care.
Discussion: Results confirm that the use of ATO/ATRA is the superior choice of induction
therapy for patients newly diagnosed with low-risk APL.
Keywords
Acute promyelocytic leukemia or APL or leukemia, acute; Arsenic trioxide or ATO;
Retinoic acid or ATRA; Chemotherapy-Free; Induction therapy
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Acute myeloid leukemia (AML) is one of the most aggressive hematologic cancers seen
in the adult population. According to the American Cancer Society (ACS; 2020), ~19,900 new
cases of AML will be diagnosed each year and d ~12,000 will result in death. The standard
treatment for AML is chemotherapy, which was first introduced in the 1940s during World War
II when mustard nitrogen was used to treat soldiers diagnosed with lymphoma from mustard gas
exposure (ChemoCare, 2020). Despite the revolutionary impact chemotherapy has made on
hematologic cancers, its benefits do not always outweigh its risks. Debilitating adverse drug
effects (ADEs), such as myelosuppression, infection, toxicities, and the risk of secondary
malignancy, accompany the administration of chemotherapy (ACS, 2020). These same ADEs are
often the cause of death for patients, more so than the cancer itself. The treatment options for a
variety of different cancers have dramatically evolved since the 1940s. Non-chemotherapy
medications are becoming the treatment option of choice and displaying similar, if not superior,
results with less ADEs (Ma et al., 2016). The combination of arsenic trioxide (ATO) and retinoic
acid (ATRA) have demonstrated excellent results for the induction therapy of newly diagnosed
acute promyelocytic leukemia (APL) in comparison to earlier treatment modalities consisting of
anthracycline based chemotherapy regimens.
Background
APL, a rare subtype of AML, accounts for 10% of all cases of myeloid leukemia. It is
characterized by translocation of chromosomes 15 and 17 that generates the promyelocytic
leukemia-retinoic acid receptor gene, PML-RARa (Leu & Mohassel, 2009). The first reports of
APL were in the 1950s when hematologists were diagnosing patients with a disease associated
with promyelocytic proliferation, hyper-acute onset, and catastrophic hemorrhage (Lo-Coco &
Cicconi, 2011). Life-threatening coagulopathy was the defining feature for APL, often leading to
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death at clinical presentation. Disseminated intravascular coagulopathy (DIC), a condition
causing fibrinolysis and procoagulant activity, is a primary cause for the hemostatic
abnormalities triggered by APL blast cells, which are seen in many patients at diagnosis or
undergoing induction therapy (Lo-Coco & Cicconi, 2011). APL was initially treated similarly to
AML, with combination chemotherapy using cytarabine and an anthracycline. Despite success at
achieving remission, this regimen was often accompanied by severe, life threatening ADEs (Park
& Tallman, 2011). In addition to myelosuppression, intracranial and pulmonary bleeds were
common, leading to an early death in ~41% of patients (Ikezoe, 2013).
In the early 1980s, ATRA was introduced when researchers discovered that leukemic
cells could undergo phenotypic revision with the use of differentiation inducers (Shen et al.,
2004). Unlike chemotherapy, ATRA could induce terminal differentiation, increasing the
remission rates above 90% and decreasing the risk of hemorrhage (Shen et al., 2004). Despite
promising results, ATRA demonstrated a new risk for patients with APL, differentiation
syndrome (DS). Characterized by a rapid release of cytokines, DS causes fever, respiratory
distress, and death if untreated (Shen et al., 2004). Thus, overall survival rates and risk of relapse
indicated that further improvement was necessary.
The 1990s introduced the opportunity for new medications when arsenic compounds used
for traditional medicines were rediscovered in China. Arsenic trioxide is a powerful antileukemic, targeting cells with the PML-RARa receptor (Abaza et al., 2017). As a single agent,
ATO has demonstrated high remission rates in untreated patients with APL. Additionally, studies
have confirmed the efficacy of ATO in relapsed patients who have received ATRA-based
regimens for induction. The synergy between ATO and ATRA is undeniable, leading to further
research on their benefits for patients newly diagnosed with APL. By understanding non-
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chemotherapy-based regimens capable of curing APL, nurses can improve patient outcomes,
regardless of treatment setting and location. The purpose of this integrative review was to
compare the use of induction therapy with ATO and ATRA to standard chemotherapy in patients
newly diagnosed with APL.
Methods
Ten articles published between 2004 and 2019 were selected. The databases used were
CINAHL, PubMed, and ProQuest Nursing and Allied Health. Articles were limited to those
published from 1980-2020 in English. Keywords and inclusion/exclusion criteria are included in
Tables 1 and 2.
An overview of the search is depicted in the PRISMA diagram (Figure 1). The search
yielded 63 articles with 18 duplicates. Titles and abstracts were reviewed and the inclusion and
exclusion criteria were applied. Two articles were exempt from this review as they were
unattainable in English. Reference lists were reviewed to identify other suitable articles that did
not result from the initial search. After applying the inclusion and exclusion criteria, 10
published articles were included.
Findings
Of the 10 studies included, 60% were published in the last 10 years. Six were
randomized controlled trials (Burnett et al., 2015; Cicconi et al., 2016; Efficace et al., 2014; LoCoco et al, 2013; Platzbecker et al., 2017; Shen et al., 2004). In five of these studies, patients
were randomized into one of two groups; the intervention group consisting of ATO/ATRA or
the control group being standard treatment with ATRA and chemotherapy (Burnett et al., 2015;
Cicconi et al., 2016; Efficace et al., 2014; Lo-Coco et al., 2013; Platzbecker et al., 2017). In the
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sixth study, patients were randomized into one of three groups: single agent ATO, single agent
ATRA, and ATO/ATRA (Shen et al., 2004). The remaining studies included three quasiexperimental designs (Abaza et al., 2017; Estey et al., 2006; Min et al., 2019) and one metaanalysis (Ma et al., 2016). Details of each study, including location, can be found in Table 3.
Categories identified included ATO/ATRA vs. ATRA with chemotherapy; risk assessment;
complete remission, survival, and relapse; and toxicity, ADEs, and quality of life (QOL).
ATO/ATRA vs. ATRA with Chemotherapy
The main objective for this review was to compare the patient-related benefits of
ATO/ATRA versus traditional treatment methods. The outcomes tested in these studies included
risk assessment, complete remission, survival, relapse, toxicity or ADEs, and QOL. Eight of the
studies compared these outcomes in patients newly diagnosed with APL who received
ATO/ATRA vs ATRA with chemotherapy (Abaza et al., 2017; Burnett et al., 2015; Cicconi et
al., 2016; Efficace et al., 2014; Estey et al., 2006; Lo-Coco et al., 2013; Ma et al., 2016;
Platzbecker et al., 2017). The chemotherapies tested against ATO included the anthracycline
idarubicin (Cicconi et al., 2016; Efficace et al., 2014; Lo-Coco et al., 2013; Ma et al., 2016;
Platzbecker et al., 2017) and the monoclonal antibody gemtuzumab (Abaza et al., 2017; Estey et
al., 2006). The idarubicin dosing was uniform at 12mg/m², while the gemtuzumab dosing ranged
from 6mg/m² (Abaza et al., 2017) to 9mg/m² (Estey et al., 2006). Burnett et al. (2015) used a
combination of both idarubicin and gemtuzumab in their study, only offering the chemotherapy
to patients who had a WBC of ≥10x10⁹ at diagnosis. The other two studies compared ATO and
ATRA, excluding chemotherapy entirely. As above, Shen et al. (2004) randomized their patients
into three groups. Min et al. (2019) took a different approach and divided their patients into three
groups based on their risk assessment. Each group received ATO/ATRA. The ATRA dosing for
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all 10 studies was uniform at 45mg/m². For induction therapy, five cycles of ATRA were given
in oral doses daily for 60 days in the first cycle. Subsequent cycles, which were treatments given
to kill any remaining cancer cells (consolidation therapy or post-remission therapy; ACS, 2020),
consisted of ATRA given orally on days 1-15. The ATO dosing was identical for all studies
(0.15mg/kg/day), except for Burnett et al. (2015) who dosed the ATO at 0.3mg/kg on days 1-5
for each cycle, then lowered the dose to 0.25mg/kg twice weekly for subsequent infusions. The
findings were unanimous when ATO/ATRA was compared to chemotherapy. Patients
experienced prolonged survival with a decreased relapse risk, demonstrating that the
combination of ATO/ATRA was as effective, if not superior to, ATRA with chemotherapy.
Risk Assessment
Most research completed pertains to low-intermediate risk patients. The standard
treatment regimen for high-risk patients continues to utilize chemotherapy; however, minimal
research has been done examining ATO/ATRA as induction therapy for the high-risk population.
Most of the studies included focused on low-intermediate risk patients (Cicconi et al., 2016;
Efficace et al., 2014; Lo-Coco et al., 2013; Platzbecker et al., 2017; Shen et al., 2004), but some
included data for the high-risk population (Abaza et al., 2017; Burnett et al., 2015; Estey et al.,
2006; Ma et al., 2016; Min et al., 2019). The risk assessment at the time of diagnosis was
uniform. Low-intermediate risk was determined if the white blood cell count (WBC) was
≤10x10⁹ and high-risk was determined if the WBC count was ≥10x10⁹. Other criteria that
increase patients’ risk is their age at diagnosis and the presence of the FLT3-ITD mutation.
Specific to the myeloid leukemias, if present upon diagnosis, this mutation represents a poorer
prognosis. In four of the studies, chemotherapy was administered to high-risk patients as part of
their regimen to induce myelosuppression (Abaza et al., 2017; Burnett et al., 2015; Estey et al.,
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2006; Ma et al., 2016). Min et al. (2019) studied 25 high-risk adults treated with ATO/ATRA as
induction therapy and found that only one death occurred from septic shock while the other 24
patients achieved complete remission with minimal toxicities. To conclude, further research on
high-risk patients receiving ATO induction therapy is necessary, especially because not all highrisk patients are candidates for chemotherapy due to preexisting conditions.
Complete Remission, Survival, and Relapse
Complete remission. One of the primary reasons as to why ATO is being investigated
for induction therapy is because of its ability to achieve a greater remission rate, prolonged
survival, and minimize relapse. To verify complete molecular remission, patients need to have a
negative RT-PCR (reverse transcription polymerase chain reaction) for the PML-RARa gene.
Some of the researchers who compared ATO to chemotherapy highlighted successful complete
remission rates (Abaza et al., 2017; Estey et al., 2006; Lo-Coco et al., 2013; Ma et al., 2016). For
those who compared ATO to gemtuzumab, the results favored ATO (Abaza et al., 2017; Estey et
al., 2006). Abaza et al. (2005) showed 96% of the ATO group achieved complete remission and
Estey et al. (2006) demonstrated complete remission in 96% of the ATO group versus 79% in the
chemotherapy group. All of the patients studied by Estey et al. (2006), achieved a complete
remission with no molecular relapses. The studies comparing ATO to idarubicin had similar
results. Lo-Coco et al. (2013) had 77 patients in the ATO group and 79 in the chemotherapy
group; all 77 patients in the ATO group achieved complete remission vs. 75 in the chemotherapy
group. In their meta-analysis, Ma et al. (2016) confirmed that there was a significant increase in
the complete remission rate of patients given ATO/ATRA compared to patients who received
ATRA and chemotherapy.
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Survival. Another important outcome is the length of time in which a patient remains
free of treatment-related complications, also known as event-free survival (EFS). Platzbecker et
al. (2017) focused on the tolerability of the medications, including survival at 24- and 50-months
post-induction. They found that EFS at 24-months was significantly higher in the ATO group
compared to the chemotherapy group (98.3% and 86.8%, respectively). Similarly, 87.3% in the
ATO group and 80% in the chemotherapy group had EFS at 50-months. Both Lo-Coco et al.
(2013) and Burnett et al. (2015) showed a significant increase in EFS in patients treated with
ATO/ATRA regimens when compared to patients given standard treatment with chemotherapy.
The differences noted between groups are due to the lower mortality from causes other than
relapse, specifically a marked reduction in hematologic toxicities in the ATO/ATRA groups.
Relapse. Not achieving remission after induction therapy is a key indicator to the
efficacy of the initial treatment. If induction therapy is successful, patients can move into
consolidation therapy; if it is not achieved, the induction therapy was ineffective in neutralizing
the leukemia, and forces the patient to enter a re-induction phase. Both Burnett et al. (2015) and
Lo-Coco et al. (2013) demonstrated a significant reduction in relapse rates when comparing the
ATO/ATRA groups to the ATRA plus chemotherapy groups. Estey et al. (2006) reported that
patients in the low-intermediate risk group achieved complete molecular remission without
relapse. Because no relapses occurred, these patients entered consolidation therapy. Additionally,
Min et al. (2019) demonstrated surprising results in high-risk patients with APL; 23 out of the 24
patients achieved remission with no documented relapses, allowing them to proceed on to
consolidation treatment. The results observed provide validation that ATO may be the superior
treatment option to both low-intermediate risk and high-risk patients with APL.
Toxicities, ADEs, and QOL
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Toxicities. Toxicities pose a real concern for patients receiving antineoplastic
medications. Some are more severe than others are, but nonetheless, put the patient at risk for
ADEs. Toxicities are associated with both ATO/ATRA and chemotherapy regimens. To start,
myelosuppression is inherently linked to chemotherapy agents, and puts patients at greater risk
for infection and bleeding (Park & Tallman, 2011). In comparison, ATO/ATRA causes minimal
myelosuppression. According to Lo-Coco et al. (2013) and Platzbecker et al. (2017), both
neutropenia and thrombocytopenia were significantly reduced in patients who received ATO.
Lo-Coco et al. (2013) reported that the patients who received chemotherapy were neutropenic
≥15 days longer than the patients who received ATO.
Hepatotoxicity is another toxicity of both treatments but is often associated more
frequently with ATO/ATRA. According to Lo-CoCo et al. (2013), 63% of the patients receiving
ATO/ATRA demonstrated toxic hepatic effects (grade three or four) during induction therapy,
while only 6% of the chemotherapy group were affected.
Lastly, heart disease and cancer often overlap, making cardiotoxicity another risk. Factors
for cardiotoxicity include age, type and dose of drug, electrolyte imbalance, and presence of
comorbid cardiovascular disease (Vineetha & Raghu, 2019). The anthracyclines are notorious for
their impact on the heart. Idarubicin can lower ejection fraction, which can have long-term
effects and delay further treatments (ChemoCare, 2020). Cardiotoxicity and reduced cardiac
function are a notable risk related to the use of ATO. QT prolongation, torsades de pointes, and
sudden death have been reported in patients receiving ATO (Vineetha & Raghu, 2019).
ADEs. In addition to toxicities, medications can have ADEs that affect the course of
treatment. Differentiation syndrome, a condition primarily associated with ATRA, causes a rapid
release of cytokines and can be fatal if left untreated. When ATRA is paired with ATO, the risk
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for DS can decrease (Park & Tallman, 2011). Several researchers mention the use of
corticosteroid prophylaxis, with dexamethasone, prednisone, or methylprednisolone, to further
prevent the DS. Platzbecker et al. (2017) noted that DS occurred in 16 of the patients who
received ATO/ATRA and nine patients who were treated with chemotherapy. Lo-Coco et al.
(2013) and Platzbecker et al. (2017) reported fatalities from DS in both the ATO and
chemotherapy groups. In addition, when patients exhibit DS symptoms, treatment may be held
until symptoms resolve with supportive care measures implemented at the bedside.
One of the signs that differentiates APL from other acute leukemias is its lethal
coagulation issues. Though not examined in the included studies, a notable complication of the
disease itself is DIC, occurring in 85% of patients with APL. In APL, the promyelocytic blast
cells secrete tissue factor directly into the bloodstream, initiating the coagulation cascade and
leading to DIC (McGraw, 2008). The use of chemotherapy elevates this risk for patients due to
the coagulative changes related to the treatment and 30% of patients receiving induction
chemotherapy suffer from hemorrhage leading to early death (Ikezoe, 2014).
QOL. Quality of life was another factor considered by some of the researchers. Efficace
et al. (2014) evaluated the impact on the patient’s well-being and potential burden from ATO.
The researchers assessed the functional and symptom scales of the Health-Related Quality-ofLife assessment tool. Patients receiving ATO had less fatigue, nausea, constipation, and appetite
suppression compared to the chemotherapy group; cognition, function, and physical aspects were
unaffected. Burnett et al. (2015) confirmed that cognition and functioning were less affected in
patients receiving ATO compared to those getting chemotherapy. Burnett et al. (2015) also noted
that the patients who received ATO had fewer hospital days, blood transfusions, platelet
transfusion, and intravenous antibiotics.
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Critical Appraisal
Despite the differences among studies, each group of researchers indicated that the use of
ATO demonstrated benefits and efficacy over chemotherapy. Both strengths and weaknesses
were identified during this analysis. The use of randomized controlled designs, thus limiting bias
in the majority of studies, is a strength in this review. Blinding was not utilized in any of the
designs. Despite its benefits, blinding may be difficult to achieve because of the risks and
complications associated with the medications. However, four of the studies were open-label
trials, meaning both the researchers and the participants knew which drug or intervention they
were receiving (Burnett et al., 2015; Efficace et al., 2014; Lo-Coco et al., 2013; Platzbecker et
al., 2017). This can be an advantage and lead to a larger volume of participants; however, open
label trials influence the ability to increase selection bias. Another strength was the various
locations studies were conducted, including the US, Italy, France, China, and Germany.
Internationally, researchers provided essential data regarding the use of ATO as induction
therapy for patients newly diagnosed with APL. This demonstrates the global awareness
necessary for this high-risk patient population.
Despite these strengths, attrition was a threat to validity. Both mortality and symptom
burden were recognized as contributing factors to attrition, and several of the researchers
identified patients who had died during induction therapy from causes unrelated to the treatment
(Abaza et al., 2017; Burnett et al., 2015; Cicconi et al., 2016; Estey et al., 2006; Lo-Coco et al.,
2013; Platzbecker et al., 2017; Ma et al., 2016; Shen et al., 2004).
There were gaps identified within this body of literature. First, there was minimal
information regarding the FLT3 mutation and how it affects the treatment and prognosis for
patients with APL. According to Cicconi et al. (2016), the FLT3 mutation is associated with
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unfavorable characteristics at diagnosis and is generally a negative indication of survival. FLT3
mutations, either FLT3-ITD or FLT3-TKD, are found in 30% of newly diagnosed patients
(Daver et al., 2018). Of the two mutations, FLT3-ITD presents with higher disease burden and
confers a poorer prognosis (Beitinjaneh et al., 2010). Because FLT3-ITD is seen in patients with
a higher WBC count, treatment with chemotherapy is necessary. Expanding on the current
research regarding FLT3 mutations in patients with APL may lead to better supportive measures
at diagnosis and impact nursing implications at the bedside.
Another gap identified was the minimal research done on high-risk patients being treated
with the ATO/ATRA. Min et al. (2019) included high-risk patients and demonstrated promising
results for future high-risk patients. Since APL is an adult disease, patients often have
comorbidities that could prevent them from receiving chemotherapy. For example, a high-risk
patient with a cardiac history may not be eligible for anthracycline-based chemotherapy.
Therefore, more research is necessary in high-risk patients to determine if ATO/ATRA is a
viable option.
Another area of future research is the use of liposomal ATRA, which was not discussed
in this review, but is a monotherapy being used as induction therapy for newly diagnosed
patients with APL. According to Ozpolat & Lopez-Berestein (2002), ATRA has improved the
treatment of APL, but medication resistance is growing. Liposomal ATRA, which has different
pharmacokinetics, has demonstrated promising results. In addition, this medication is given
intravenously, allowing patients who are unable to tolerate oral medications an effective
treatment option(Ozolat & Lopez-Berestein, 2002).
There was a noticeable lack of nursing implications discussed within this body of
literature, demonstrating a need for further research regarding the role of the nurse in managing
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patients with APL. Nurses have an integral role in caring for patients with leukemia as they assist
in managing treatment related toxicities, provide care coordination, and delivering education and
support throughout treatment.
Implications
Although there were differences in setting, sample, and study design, each study had
consistent findings indicating that the use of ATO/ATRA as induction therapy was efficient and
beneficial when compared to chemotherapy. To further support this conclusion, more studies
need to be conducted, especially focusing on genetic mutations and high-risk patients who are
not eligible for chemotherapy. Moreover, protocols to prevent ADEs should be evaluated to
determine which method provides the best results for patient safety.
As stated, nursing implications were not discussed within this body of literature but
should be strongly considered. Nurses should be competent in the care of patients with APL,
including understanding the disease process and treatment course. This would allow nurses to
better educate their patients, safely administer medications, recognize ADEs and toxicities, and
provide support throughout the treatment course.
Oncology nurses are responsible for understanding the ADEs related to each medication
and should be familiar with supportive measures to monitor patient status and promote safety.
This includes thorough physical assessments, along with laboratory and diagnostic test
monitoring. These skills are necessary, especially for patients with DS or DIC.
Nurses also oversee and direct education for patients and their families. Education is
imperative, as patients and families will have many questions and concerns. Evidence-based
reinforcement from nursing can assist patient and family understanding. Nurses should be able to
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explain the purpose and ADEs of each drug the patient is receiving, and treatment trajectory. In
addition, nurses should offer support both in and outside of the hospital setting.
Conclusion
This review focused on successfully treating APL, a complex disease, with alternative
methods. APL is a relentless disease, often associated with a grim ending. Aggressive treatment
methods using chemotherapy have been successful, but yield toxic ADEs. Since the 1980s,
treatment options for leukemia have improved, with a focus on disease eradication and QOL
maximization. Medications, such as ATO and ATRA demonstrate the ability to combat leukemia
and achieve lasting remission. The research completed on the use of ATO for induction therapy
in patients with APL validates the necessity for continued research on this unique treatment.
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Appendix A

Table 1: Search Strategy

Database
CINAHL

PubMed

ProQuest Nursing and
Allied Health

Search Strategy
Medication treatment or induction treatment or induction therapy
and acute promyelocytic leukemia or APL and arsenic or arsenic
trioxide or ATO and retinoic acid or ATRA and without
chemotherapy or chemotherapy free
Cancer treatment protocols or induction therapy and leukemia,
acute promyelocytic or APL and arsenic or arsenic trioxide or ATO
and retinoic acid or ATRA and without chemotherapy or
chemotherapy free
Medication treatment or induction treatment or induction therapy
and acute promyelocytic leukemia or APL and arsenic or arsenic
trioxide or ATO and retinoic acid or ATRA and without
chemotherapy or chemotherapy free
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Appendix B

Table 2: Inclusion and Exclusion Criteria

Inclusion Criteria

● Adult males and females (18+)
● International studies
● Peer reviewed

Exclusion Criteria

●
●
●
●

Pediatric patients
Consolidation regimens
Bone marrow transplant
Induction therapy other than
ATO/ATRA
● Chemotherapy-only regimens
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Appendix C

Table 3: PRISMA Diagram
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Appendix D

Table 4: Study Characteristics

Authors

Abaza et
al., 2017

Burnett et
al., 2015

Cicconi et
al., 2016

Efficace
et al.,
2014

Estey et
al., 2006

Lo-CoCo
et al.,
2013

Ma et al.,
2016

Min et al.,
2019

Platzbeck
er et al.,
2017

Shen et
al., 2004

Sample
Size
Type of
Design

187

235

159

162

49

162

585

25

263

61

QuasiExperime
ntal

RCTOpen
label

RCT

RCTOpen
label

QuasiExperime
ntal

MetaAnalysis

QuasiExperime
ntal

RCTOpen
label

RCT

ATO/
ATRA vs.
Chemothe
rapy
Outcomes
Measured
Relapse
rates
Survival
Remissio
n
Toxicities
ADEs
QOL
Location

Yes

Yes

Yes

Yes

Yes

Phase 3
multicent
er trial,
open label
Yes

Yes

ATO/
ATRA
Only

Yes

ATO/
ATRA
Only

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓
✓

✓

✓

US

✓

✓

UK

Italy

Italy

US

Italy

✓

✓
✓
✓

✓

UK

Germany

Germany

China

